Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance pembrolizumab versus observation after 6 months of chemoimmunotherapy induction in stage IV NSCLC
2021-006044-27Phase 2Active
- Sponsor
- IFCT
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: 18-month landmark overall survival from inclusion. Started Dec 2021; status: active.
02
Drugs
pembrolizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-006044-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006044-27.